BEIJING, June 11, 2018 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading
provider of biopharmaceutical products in China, today
announced that the company has relaunched its website, at
www.sinovacbio.com.
On April 30, 2018, the Company
temporarily blocked access to its websites upon discovering that
Aihua Pan, the Chairman of the Board of the Company's
controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac
Beijing"), who was appointed by Sinobioway Biomedicine Co., Ltd.
("Sinobioway"), the minority shareholder of Sinovac Beijing,
inappropriately and without authorization seized control of the
Company's websites.
The relaunched website will allow all regulators, shareholders,
customers, employees, and other interested stakeholders to access
relevant materials, as the Company moves forward in its mission to
develop vaccines that enhance health in China and around the world and create
shareholder value.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical
Company that focuses on the research, development, manufacturing
and commercialization of vaccines that protect against human
infectious diseases. Sinovac's product portfolio includes vaccines
against enterovirus71, or EV71, hepatitis A and B, seasonal
influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza
(swine flu), and mumps. Healive, the hepatitis A vaccine
manufactured by the Company has passed the assessment under WHO
Prequalification procedures in 2017. The EV71 vaccine, an
innovative vaccine developed by Sinovac against hand foot and mouth
disease caused by EV71, was commercialized in China in
2016. In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. The
Company is developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines
in China, while also exploring growth opportunities in
international markets. The Company has exported select vaccines to
over 10 countries in Asia and South America. For more
information, please visit the Company's website at
www.sinovacbio.com.
Safe Harbor Statement
This announcement may include certain
statements that are not descriptions of historical facts, but are
forward-looking statements. These statements are made under the
"safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such
statements.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Investors:
ICR Inc.
Bill Zima
Tel: 1-203--682-8233
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/sinovac-biotech-relaunches-company-website-300663923.html
SOURCE Sinovac Biotech Ltd.